12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fanapt iloperidone regulatory update

Vanda disclosed in its 2Q12 earnings that it requested an extension to submit responses to Day 180 questions from EMA's CHMP related to the review of an MAA for iloperidone to treat schizophrenia. The company, which received the questions in July, hopes...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >